Patients with CLL can be Retreated with Venetoclax
April 8, 2026
Black and Hispanic patients with CLL were less likely than White patients to be prescribed guideline-recommended novel therapies.
Black and Hispanic patients with CLL were less likely than White patients to be prescribed guideline-recommended novel therapies.
After patients with CLL were treated with venetoclax-obinutuzumab, their immune systems gradually recovered, but this was slower in patients with deep responses.
Though it is still early, the combination of pirtobrutinib-venetoclax-obinutuzumab appears to have good efficacy in patients with Richter transformation.
First-line treatment with combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in patients with CLL.
The FDA has approved acalabrutinib and venetoclax as the first all oral combination for previously untreated CLL patients based on the AMPLIFY trial data.
An ongoing phase 2 clinical trial is testing whether adding venetoclax to first-line BTK inhibitor therapy can deepen remissions for CLL patients.
An ongoing phase 2 clinical trial is evaluating the efficacy and tolerability of fixed-duration zanubrutinib plus venetoclax for relapsed / refractory CLL.
MRD guided venetoclax based therapy can lead to durable remissions in both the frontline and relapsed/refractory (R/R) setting in CLL
An ongoing phase 2 clinical trial is studying whether preemptive acalabrutinib plus venetoclax can prevent infections in newly diagnosed CLL patients.